H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance

AngioDynamics, Inc. (NASDAQ:ANGO) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 6, H.C. Wainwright reiterated its Buy rating on AngioDynamics (NASDAQ:ANGO) with a price target of $16, following robust fiscal Q1 2026 results.

The company posted $75.7 million in net sales, up 12.2% year-over-year, driven by a 26.1% surge in Med Tech revenue. Key products like AlphaVac and AngioVac saw sales jump over 50% and 37%, respectively, contributing to a 91% stock return over the past year.

Despite a net loss of $10.9 million, AngioDynamics reported positive adjusted EBITDA of $2.2 million. U.S. and international sales rose 11.7% and 15.6%, respectively. The company also raised its full-year guidance, projecting net sales of $308–313 million and adjusted EBITDA of $6.0–10.0 million, while maintaining its gross margin outlook.

AngioDynamics, Inc. (NASDAQ:ANGO) is a global medical technology company that develops, produces, and markets devices used in the treatment of peripheral vascular disease, cancer, and surgical conditions. Its product portfolio supports both diagnostic and therapeutic procedures across the U.S. and international healthcare markets.

While we acknowledge the potential of ANGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks to Buy As Gold Rallies and 13 Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.

Disclosure: None. This article is originally published at Insider Monkey.